- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00160693
Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis
A Phase III, Multicenter, Open-Label Long-Term Study to Assess the Safety and Tolerability of CDP870 400 mg Subcutaneously Every 4 Weeks, in Subjects With Rheumatoid Arthritis
Przegląd badań
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 3
Rozszerzony dostęp
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Graz, Austria
-
Klagenfurt, Austria
-
Vienna, Austria
-
-
-
-
-
Antwerpen, Belgia
-
Diepenbeek, Belgia
-
Liege, Belgia
-
Merksem, Belgia
-
-
-
-
-
Ceske Budejovice, Czechy
-
Liberec, Czechy
-
Ostrava Trebovice, Czechy
-
Prague 2, Czechy
-
Praha4 -krc, Czechy
-
Uherske Hradiste, Czechy
-
-
-
-
-
Dublin, Irlandia
-
Waterford, Irlandia
-
-
-
-
-
Berlin, Niemcy
-
Gortlitz, Niemcy
-
Hamburg, Niemcy
-
Jena, Niemcy
-
Koln, Niemcy
-
Leipzig, Niemcy
-
Ratingen, Niemcy
-
-
-
-
Alabama
-
Huntsville, Alabama, Stany Zjednoczone
-
-
Arizona
-
Paradise Valley, Arizona, Stany Zjednoczone
-
-
District of Columbia
-
Washington, District of Columbia, Stany Zjednoczone
-
-
Florida
-
Aventura, Florida, Stany Zjednoczone
-
Clearwater, Florida, Stany Zjednoczone
-
Ocala, Florida, Stany Zjednoczone
-
Orlando, Florida, Stany Zjednoczone
-
Tampa, Florida, Stany Zjednoczone
-
-
Idaho
-
Coeur d'Alene, Idaho, Stany Zjednoczone
-
-
Illinois
-
Springfield, Illinois, Stany Zjednoczone
-
-
Kansas
-
Wichita, Kansas, Stany Zjednoczone
-
-
Maryland
-
Wheaton, Maryland, Stany Zjednoczone
-
-
Massachusetts
-
Fall River, Massachusetts, Stany Zjednoczone
-
-
Missouri
-
Saint Louis, Missouri, Stany Zjednoczone
-
-
Nebraska
-
Lincoln, Nebraska, Stany Zjednoczone
-
-
North Carolina
-
Charlotte, North Carolina, Stany Zjednoczone
-
-
Ohio
-
Cleveland, Ohio, Stany Zjednoczone
-
Dayton, Ohio, Stany Zjednoczone
-
-
Pennsylvania
-
Erie, Pennsylvania, Stany Zjednoczone
-
West Reading, Pennsylvania, Stany Zjednoczone
-
-
South Carolina
-
Charleston, South Carolina, Stany Zjednoczone
-
-
Tennessee
-
Memphis, Tennessee, Stany Zjednoczone
-
-
Texas
-
Austin, Texas, Stany Zjednoczone
-
Dallas, Texas, Stany Zjednoczone
-
Duncanville, Texas, Stany Zjednoczone
-
Lubbock, Texas, Stany Zjednoczone
-
San Antonio, Texas, Stany Zjednoczone
-
San Diego, Texas, Stany Zjednoczone
-
-
Washington
-
Everett, Washington, Stany Zjednoczone
-
-
-
-
-
Birmingham, Zjednoczone Królestwo
-
Cannock, Zjednoczone Królestwo
-
Colchester, Zjednoczone Królestwo
-
Glasgow, Zjednoczone Królestwo
-
Harrogate, Zjednoczone Królestwo
-
London, Zjednoczone Królestwo
-
Manchester, Zjednoczone Królestwo
-
Oxford, Zjednoczone Królestwo
-
Peterborough, Zjednoczone Królestwo
-
Wirral, Zjednoczone Królestwo
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Participation in CZP trial C87014 or C87011
- If female and of childbearing potential, she agrees to participate in this study by providing written informed consent, has been using adequate contraception since her last menses, will use adequate contraception during the study and for 12 weeks after the last dose of study drug (or longer if required by local regulations), is not lactating, and has had a negative urine pregnancy test on the day of receiving the first dose of study drug
- Must have provided written informed consent before undergoing any study procedures
Exclusion Criteria:
- History (Hx) of chronic infection, serious or life-threatening infection - (including Herpes Zoster) within 6 months prior, or any current symptom indicating infection
- Current or recent Hx of severe, progressive and/or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological or cerebral disease
- Any finding indicative of Tuberculosis at end of previous study
- Known HIV infection
- Persistently abnormal AST (Aspartate Aminotransferase) or ALT (Alanine Aminotransferase) results (> 2 times upper limit of normal)
- Hemoglobin (Hgb) levels < 9 g/dL or Hematocrit < 30 %
- Total White Blood Cell (WBC) count of < 3.0 x 100/L (< 3000/mm^3)
- Platelet count < 100 x 100 L (100,000/mm^3)
- Serum creatinine > 1.5 times upper limit of normal based on patient age and sex
- Receipt of any biological therapies for RA in 6 months prior to study entry or any prior treatment (tx) with Tumor Necrosis Factor (TNF) blocking agent (excluding CDP870)
- Receipt of any vaccination (live, attenuated or killed) in 8 weeks prior to Baseline
- Any other condition which the Principal Investigator judges would make patient unsuitable for study participation
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Certolizumab Pegol
|
400 mg of Certolizumab Pegol subcutaneously every 4 Weeks
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Percentage of Subjects With at Least One Adverse Event (AE) During the Study Period of 8 Years
Ramy czasowe: From first dose of CZP up to 8 years
|
An AE is any untoward medical occurrence in a subject or trial subject that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage. First dose of CZP was at Baseline of one of the feeder studies C87011 [NCT00548834] or C87014 [NCT00544154] for subjects randomized to CZP, or at First Visit (Week 0) of this study for subjects randomized to Placebo. |
From first dose of CZP up to 8 years
|
Percentage of Subjects Who Withdrew Due to an Adverse Event (AE) During the Study Period of 8 Years
Ramy czasowe: From First Visit (Week 0 in this study) up to 8 years
|
An AE is any untoward medical occurrence in a subject or trial subject that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage. The results of this Primary Outcome Measure are summarized from the Adverse Event pages of the Case Report Forms. |
From First Visit (Week 0 in this study) up to 8 years
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Percentage of Subjects Meeting the American College of Rheumatology 20% Response Criteria (ACR20) at Week 52
Ramy czasowe: From Baseline to Week 52
|
The assessments are based on a 20% or greater improvement from Baseline to Week 52 in the number of tender joints, a 20% or more improvement in the number of swollen joints, and a 20% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP). Baseline is Baseline of the respective feeder study. |
From Baseline to Week 52
|
Percentage of Subjects Meeting the American College of Rheumatology 20% Response Criteria (ACR20) at Week 100
Ramy czasowe: From Baseline to Week 100
|
The assessments are based on a 20% or greater improvement from Baseline to Week 100 in the number of tender joints, a 20% or more improvement in the number of swollen joints, and a 20% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP). Baseline is Baseline of the respective feeder study. |
From Baseline to Week 100
|
Percentage of Subjects Meeting the American College of Rheumatology 20% Response Criteria (ACR20) at Week 160
Ramy czasowe: From Baseline to Week 160
|
The assessments are based on a 20% or greater improvement from Baseline to Week 160 in the number of tender joints, a 20% or more improvement in the number of swollen joints, and a 20% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP). Baseline is Baseline of the respective feeder study. |
From Baseline to Week 160
|
Percentage of Subjects Meeting the American College of Rheumatology 20% Response Criteria (ACR20) at Week 208
Ramy czasowe: From Baseline to Week 208
|
The assessments are based on a 20% or greater improvement from Baseline to Week 208 in the number of tender joints, a 20% or more improvement in the number of swollen joints, and a 20% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP). Baseline is Baseline of the respective feeder study. |
From Baseline to Week 208
|
Percentage of Subjects Meeting the American College of Rheumatology 20% Response Criteria (ACR20) at Week 256
Ramy czasowe: From Baseline to Week 256
|
The assessments are based on a 20% or greater improvement from Baseline to Week 256 in the number of tender joints, a 20% or more improvement in the number of swollen joints, and a 20% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP). Baseline is Baseline of the respective feeder study. |
From Baseline to Week 256
|
Percentage of Subjects Meeting the American College of Rheumatology 20% Response Criteria (ACR20) at Week 316
Ramy czasowe: From Baseline to Week 316
|
The assessments are based on a 20% or greater improvement from Baseline to Week 316 in the number of tender joints, a 20% or more improvement in the number of swollen joints, and a 20% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP). Baseline is Baseline of the respective feeder study. |
From Baseline to Week 316
|
Percentage of Subjects Meeting the American College of Rheumatology 20% Response Criteria (ACR20) at Completion Visit or Early Withdrawal Visit
Ramy czasowe: From Baseline to Completion Visit/ early Withdrawal Visit, up to 8 years
|
The assessments are based on a 20% or greater improvement from Baseline to the Completion Visit or early Withdrawal Visit in the number of tender joints, a 20% or more improvement in the number of swollen joints, and a 20% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).
|
From Baseline to Completion Visit/ early Withdrawal Visit, up to 8 years
|
Percentage of Subjects Meeting the American College of Rheumatology 50% Response Criteria (ACR50) at Completion Visit or Early Withdrawal Visit
Ramy czasowe: From Baseline to Completion Visit/ early Withdrawal Visit, up to 8 years
|
The assessments are based on a 50% or greater improvement from Baseline to the Completion Visit or early Withdrawal Visit in the number of tender joints, a 50% or more improvement in the number of swollen joints, and a 50% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).
|
From Baseline to Completion Visit/ early Withdrawal Visit, up to 8 years
|
Percentage of Subjects Meeting the American College of Rheumatology 70% Response Criteria (ACR70) at Completion Visit or Early Withdrawal Visit
Ramy czasowe: From Baseline to Completion Visit/ early Withdrawal Visit, up to 8 years
|
The assessments are based on a 70% or greater improvement from Baseline to the Completion Visit or early Withdrawal Visit in the number of tender joints, a 70% or more improvement in the number of swollen joints, and a 70% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).
|
From Baseline to Completion Visit/ early Withdrawal Visit, up to 8 years
|
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ- DI) at Completion Visit or Early Withdrawal Visit
Ramy czasowe: From Baseline to Completion Visit/ early Withdrawal Visit, up to 8 years
|
The HAQ-DI assesses the degree of difficulty experienced in eight domains (Dressing and Grooming, Arising, Eating, Walking, Hygiene, Reach, Gripping, Other Activities) of daily living activities using 20 questions.
The HAQ-DI is calculated by summing the domain scores and dividing them by the number of domains.
It ranges from 0 (no difficulty) to 3 (unable to do).
Negative values indicate an improvement from Baseline to the Post-Baseline Visit with larger negative values showing a better improvement.
|
From Baseline to Completion Visit/ early Withdrawal Visit, up to 8 years
|
Percentage of Subjects Who Withdrew Due to Lack of Efficacy During the Study Period of 8 Years
Ramy czasowe: From First Visit (Week 0 in this study) up to 8 years
|
From First Visit (Week 0 in this study) up to 8 years
|
|
Percentage of Subjects Utilizing Common Additional Arthritis Medications During the Study Period of 8 Years
Ramy czasowe: From First Visit (Week 0 in this study) up to 8 years
|
This Secondary Outcome Measure shows additional arthritis medications received by at least 20% of subjects during the 8-year study.
|
From First Visit (Week 0 in this study) up to 8 years
|
Współpracownicy i badacze
Sponsor
Publikacje i pomocne linki
Przydatne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby układu odpornościowego
- Choroby Autoimmunologiczne
- Choroby stawów
- Choroby układu mięśniowo-szkieletowego
- Choroby reumatyczne
- Choroby tkanki łącznej
- Artretyzm
- Zapalenie stawów, reumatoidalne
- Fizjologiczne skutki leków
- Środki przeciwreumatyczne
- Środki immunosupresyjne
- Czynniki immunologiczne
- Certolizumab Pegol
Inne numery identyfikacyjne badania
- C87015
- 2005-002617-21 (Numer EudraCT)
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Certolizumab Pegol
-
UCB PharmaWycofaneChoroba Leśniowskiego-Crohna
-
UCB PharmaZakończony
-
Atlanta Gastroenterology AssociatesUCB PharmaNieznany
-
UCB Pharma SAZakończonyChoroba CrohnaStany Zjednoczone, Australia, Austria, Białoruś, Belgia, Bułgaria, Kanada, Czechy, Dania, Estonia, Niemcy, Węgry, Izrael, Włochy, Nowa Zelandia, Norwegia, Polska, Federacja Rosyjska, Serbia, Singapur, Słowenia, Afryka Południowa, Hi... i więcej
-
UCB PharmaZakończonyReumatyzmDania, Holandia, Polska, Szwecja
-
University of WashingtonUniversity of Pennsylvania; UCB PharmaZakończonyWrzodziejące zapalenie okrężnicyStany Zjednoczone
-
UCB PharmaZakończonyChoroba CrohnaStany Zjednoczone, Francja, Włochy, Zjednoczone Królestwo, Belgia, Niemcy, Hiszpania, Szwajcaria, Kanada, Holandia, Austria, Szwecja
-
UCB PharmaZakończonyReumatyzmStany Zjednoczone, Francja, Włochy, Niemcy, Hiszpania, Kanada, Holandia